ROYALTY PHARMA PLC- CL A (RPRX)
GB00BMVP7Y09 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to RPRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 46.41. This target is 65.1% above the current price.
RPRX was analyzed by 14 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about RPRX.
In the previous month the buy percentage consensus was at a similar level.
RPRX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-12 | B of A Securities | Maintains | Buy -> Buy |
| 2024-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-02-20 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-11-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-10-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-07-11 | Morgan Stanley | Reiterate | Overweight -> Overweight |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-04-10 | Morgan Stanley | Maintains | Overweight |
| 2023-02-16 | UBS | Maintains | Buy |
| 2022-12-06 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-10-18 | JP Morgan | Maintains | Overweight |
| 2022-08-08 | Morgan Stanley | Maintains | Overweight |
| 2022-07-14 | Tigress Financial | Maintains | Buy |
| 2022-06-14 | UBS | Initiate | Buy |
| 2022-05-13 | ScotiaBank | Initiate | Outperform |
| 2022-04-27 | Goldman Sachs | Initiate | Buy |
| 2022-04-14 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2021-10-29 | Citigroup | Upgrade | Neutral -> Buy |
| 2021-08-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-07-30 | Tigress Financial | Initiate | Buy |